Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis (review)

被引：0
|
作者：
Boyko, A. N. [1 ]
Gusev, E. I.
机构：
[1] Pirogov Russian Natl Res Med Univ, Moscow, Russia
来源：
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA | 2013年 / 113卷 / 02期
关键词：
multiple sclerosis; therapy; neuroprotection; laquinimod; SECONDARY PROGRESSIVE MS; KAPPA-B; LINOMIDE; ABR-215062; TRIAL;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
New oral therapies of MS cause great attention. This review includes data on the II and III phase clinical studies of laquinimod (LAQ) - a new oral therapy for MS with immunoregulatory, anti inflammatory and neuroprotective action. LAQ has no immunosupressive effects and has a very good safety and tolerability profile. Data of phase III studies including 2437 MS patients confirmed positive effect of LAQ on relapse rate and disability progression. These clinical results were supported by the MRI data, showing also a significant slowing of the brain atrophy. Russian neurological clinics actively participated in all LAQ clinical trials: 241 MS patients from 11 centers from Russia took part in the phase II trials. The data in this subgroup confirm all changes, registered in the whole group of patients.
引用
收藏
页码：93 / 99
页数：7
相关论文
共 50 条
  • [21] Changes in Immune Parameters Following Commencement of Laquinimod, a Novel Oral Therapy for the Treatment of Multiple Sclerosis
    Lund, Brett T.
    Stasiolek, Mariusz
    Kelland, Eve E.
    Gaupp, Stefanie
    Gilmore, Wendy
    Linker, Ralf
    Gold, Ralf
    Weiner, Leslie P.
    NEUROLOGY, 2011, 76 (09) : A139 - A139
  • [22] MULTIPLE SCLEROSIS Oral laquinimod for MS-bringing the brain into focus
    Brueck, Wolfgang
    Vollmer, Timothy
    NATURE REVIEWS NEUROLOGY, 2013, 9 (12) : 664 - 665
  • [23] Regular review - Drug treatment of multiple sclerosis
    Polman, CH
    Uitdehaag, BMJ
    BRITISH MEDICAL JOURNAL, 2000, 321 (7259): : 490 - 494
  • [24] TREATMENT OF MULTIPLE SCLEROSIS - A REVIEW OF DRUG THERAPY
    SCHUMACHER, GA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1950, 143 (14): : 1241 - 1250
  • [25] Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis
    Constantinescu, Simona E.
    Constantinescu, Cris S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (01) : 49 - 57
  • [26] Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod
    Majlathi, Zsofia
    Annus, Adam
    Vecsei, Laszlo
    CURRENT DRUG TARGETS, 2018, 19 (07) : 805 - 814
  • [27] Pathogenetic treatment of multiple sclerosis: the present and the future
    Boyko, A. N.
    Stolyarov, I. D.
    Sidorenko, T. V.
    Kulakova, O. V.
    Kolyak, E. V.
    Petrov, A. M.
    Ilves, A. G.
    Nikiforova, I. G.
    Favorova, O. O.
    Gusev, E. I.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2009, 109 (07) : 90 - +
  • [28] Phenotype and Functional Properties of Monocytes from Patients under Laquinimod, a Novel Oral Therapy for the Treatment of Multiple Sclerosis
    Stasiolek, Mariusz
    Linker, Ralf
    Gaupp, Stefanie
    Thone, Jan
    Nisimov, Liat Hayardeny
    Gold, Ralf
    NEUROLOGY, 2011, 76 (09) : A134 - A134
  • [29] Neurodegeneration in multiple sclerosis and the neuroprotective effect of glatiramer acetate: a literature review
    Shmidt, T. E.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2012, 112 (09) : 123 - 128
  • [30] Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis
    Varrin-Doyer, Michel
    Zamvil, Scott S.
    Schulze-Topphoff, Ulf
    EXPERIMENTAL NEUROLOGY, 2014, 262 : 66 - 71
12345